These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Designed ankyrin repeat proteins (DARPins) as novel isoform-specific intracellular inhibitors of c-Jun N-terminal kinases. Parizek P; Kummer L; Rube P; Prinz A; Herberg FW; Plückthun A ACS Chem Biol; 2012 Aug; 7(8):1356-66. PubMed ID: 22568706 [TBL] [Abstract][Full Text] [Related]
4. Inhibitors of c-Jun N-terminal kinases: an update. Koch P; Gehringer M; Laufer SA J Med Chem; 2015 Jan; 58(1):72-95. PubMed ID: 25415535 [TBL] [Abstract][Full Text] [Related]
5. The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting. Bogoyevitch MA Bioessays; 2006 Sep; 28(9):923-34. PubMed ID: 16937364 [TBL] [Abstract][Full Text] [Related]
6. Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases. Zhu Y; Shuai W; Zhao M; Pan X; Pei J; Wu Y; Bu F; Wang A; Ouyang L; Wang G J Med Chem; 2022 Mar; 65(5):3758-3775. PubMed ID: 35200035 [TBL] [Abstract][Full Text] [Related]
7. JNK inhibitors as anti-inflammatory and neuroprotective agents. Graczyk PP Future Med Chem; 2013 Apr; 5(5):539-51. PubMed ID: 23573972 [TBL] [Abstract][Full Text] [Related]
8. Pyrazole derivatives as potent inhibitors of c-Jun N-terminal kinase: synthesis and SAR studies. Doma A; Kulkarni R; Palakodety R; Sastry GN; Sridhara J; Garlapati A Bioorg Med Chem; 2014 Nov; 22(21):6209-19. PubMed ID: 25261929 [TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of 1-aryl-5-anilinoindazoles as c-Jun N-terminal kinase inhibitors. Jiang R; Frackowiak B; Shin Y; Song X; Chen W; Lin L; Cameron MD; Duckett DR; Kamenecka TM Bioorg Med Chem Lett; 2013 May; 23(9):2683-7. PubMed ID: 23518277 [TBL] [Abstract][Full Text] [Related]
10. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Waetzig V; Czeloth K; Hidding U; Mielke K; Kanzow M; Brecht S; Goetz M; Lucius R; Herdegen T; Hanisch UK Glia; 2005 May; 50(3):235-46. PubMed ID: 15739188 [TBL] [Abstract][Full Text] [Related]
12. A novel retro-inverso peptide is a preferential JNK substrate-competitive inhibitor. Ngoei KR; Catimel B; Milech N; Watt PM; Bogoyevitch MA Int J Biochem Cell Biol; 2013 Aug; 45(8):1939-50. PubMed ID: 23792175 [TBL] [Abstract][Full Text] [Related]
13. Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead. Palmer WS; Alam M; Arzeno HB; Chang KC; Dunn JP; Goldstein DM; Gong L; Goyal B; Hermann JC; Hogg JH; Hsieh G; Jahangir A; Janson C; Jin S; Ursula Kammlott R; Kuglstatter A; Lukacs C; Michoud C; Niu L; Reuter DC; Shao A; Silva T; Trejo-Martin TA; Stein K; Tan YC; Tivitmahaisoon P; Tran P; Wagner P; Weller P; Wu SY Bioorg Med Chem Lett; 2013 Mar; 23(5):1486-92. PubMed ID: 23352510 [TBL] [Abstract][Full Text] [Related]
14. Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): optimization for JNK potency and physicochemical properties. Gong L; Han X; Silva T; Tan YC; Goyal B; Tivitmahaisoon P; Trejo A; Palmer W; Hogg H; Jahagir A; Alam M; Wagner P; Stein K; Filonova L; Loe B; Makra F; Rotstein D; Rapatova L; Dunn J; Zuo F; Dal Porto J; Wong B; Jin S; Chang A; Tran P; Hsieh G; Niu L; Shao A; Reuter D; Hermann J; Kuglstatter A; Goldstein D Bioorg Med Chem Lett; 2013 Jun; 23(12):3565-9. PubMed ID: 23664880 [TBL] [Abstract][Full Text] [Related]
15. Structure-driven HtL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity. Stocks MJ; Barber S; Ford R; Leroux F; St-Gallay S; Teague S; Xue Y Bioorg Med Chem Lett; 2005 Jul; 15(14):3459-62. PubMed ID: 15950471 [TBL] [Abstract][Full Text] [Related]
16. Allosteric Modulation of JNK Docking Site Interactions with ATP-Competitive Inhibitors. Lombard CK; Davis AL; Inukai T; Maly DJ Biochemistry; 2018 Oct; 57(40):5897-5909. PubMed ID: 30211540 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors. Song X; Chen W; Lin L; Ruiz CH; Cameron MD; Duckett DR; Kamenecka TM Bioorg Med Chem Lett; 2011 Dec; 21(23):7072-5. PubMed ID: 22004719 [TBL] [Abstract][Full Text] [Related]
18. JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases. Kumar A; Singh UK; Kini SG; Garg V; Agrawal S; Tomar PK; Pathak P; Chaudhary A; Gupta P; Malik A Future Med Chem; 2015; 7(15):2065-86. PubMed ID: 26505831 [TBL] [Abstract][Full Text] [Related]
19. Cerebral ischemia provokes a profound exchange of activated JNK isoforms in brain mitochondria. Zhao Y; Herdegen T Mol Cell Neurosci; 2009 Jun; 41(2):186-95. PubMed ID: 19289169 [TBL] [Abstract][Full Text] [Related]
20. JNK signaling as a target for anticancer therapy. Abdelrahman KS; Hassan HA; Abdel-Aziz SA; Marzouk AA; Narumi A; Konno H; Abdel-Aziz M Pharmacol Rep; 2021 Apr; 73(2):405-434. PubMed ID: 33710509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]